Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Patients with chronic hepatitis C (CHC) treated with direct‐acting antivirals (DAAs) are still at risk for developing hepatocellular carcinoma (HCC) even after achieving sustained virologic response (SVR). Liver stiffness measurement (LSM) on imaging has been investigated as a predictor of HCC occurrence.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Objectives</h3><p>To provide systematic summary of the predictive value of LSM in predicting HCC occurrence in HCV patients treated with DAA.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>A comprehensive literature search of the PubMed‐MEDLINE and EMBASE databases was performed to identify studies that evaluated the predictive value of LSM in CHC patients treated with DAAs. Pooled hazard ratio (HR) comparing HCC occurrence between patients with positive and negative results on LSM was calculated for all studies and various subgroups. Subgroup analyses and meta‐regression were performed.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Review of 135 candidate articles identified 8 eligible articles with a total of 3398patients for qualitative review and meta‐analysis. The pooled HR for HCC occurrence determined by LSM was 3.43 [95% confidence interval (CI), 1.63‐7.19] with heterogeneity (I<sup>2</sup>=81.87%, p<0.001), thus indicating that LSM might be helpful for predicting HCC occurrence. In subgroup analyses, pooled HRs were different according to the study design [2.29 (95% CI, 0.96‐5.45) for retrospective studies; 4.61(2.44‐8.71) for prospective studies], study population [4.00(2.00‐7.99)for CHC; 2.64 (0.99‐7.00) for CHC with liver cirrhosis] and LSM parameter [3.17(1.35‐7.41) for baseline LSM; 4.19(1.89‐9.29) for others]. In multivariate meta‐regression, study design was the only influencing factor for pooled HR for HCC occurrence (p< 0.05). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Consistent evidence demonstrated the predictive value of LSM for HCC occurrence in CHC patients treated with DAA. The significant influencing factor for risk of HCC occurrence indicated by LSM was study design.</p></section>

Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience

Liver Stiffness Evaluation in Chronic Hepatitis C Patients with Cirrhosis before and after Direct-Acting Antivirals

Liver Stiffness Values to Predict Occurrence and Recurrence of Hepatocellular Carcinoma

Title : Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy : a 2-year prospective study Running head : Liver stiffness for liver fibrosis monitoring Authors :

Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study.

Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C

Multiparametric liver assessment in patients successfully treated for hepatitis C: a 4-year follow-up

Liver stiffness and spleen stiffness predict distinct liver-related events after hepatitis C eradication with direct-acting antivirals

Effect of pegylated interferon combined with ribavirin on chronic hepatitis C liver stiffness values

Inflammation response and liver stiffness: predictive model of regression of hepatic stiffness after sustained virological response in cirrhotics patients with chronic hepatitis C

Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study

Increasing liver stiffness is associated with higher incidence of hepatocellular carcinoma in hepatitis C infection and non-alcoholic fatty liver disease-A population-based study

Noninvasive assessment of liver fibrosis can predict clinical outcomes at late follow-up after a sustained virological response in HCV patients?

Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients after Direct-Acting Antiviral Therapy.

Impact of liver‐stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct‐acting antivirals: A systematic review and time‐to‐event meta‐analysis

Shear-wave elastography to predict hepatocellular carcinoma after hepatitis C virus eradication: A systematic review and meta-analysis

On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis

Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV)

Longitudinal Monitoring of Liver Stiffness by Acoustic Radiation Force Impulse Imaging in Patients with Chronic Hepatitis B Receiving Entecavir.

Longitudinal Monitoring of Liver Fibrosis Status by Transient Elastography in Chronic Hepatitis B Patients During Long-Term Entecavir Treatment.

Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis